These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30737146)

  • 21. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8
    Wang K; Coutifaris P; Brocks D; Wang G; Azar T; Solis S; Nandi A; Anderson S; Han N; Manne S; Kiner E; Sachar C; Lucas M; George S; Yan PK; Kier MW; Laughlin AI; Kothari S; Giles J; Mathew D; Ghinnagow R; Alanio C; Flowers A; Xu W; Tenney DJ; Xu X; Amaravadi RK; Karakousis GC; Schuchter LM; Buggert M; Oldridge D; Minn AJ; Blank C; Weber JS; Mitchell TC; Farwell MD; Herati RS; Huang AC
    Cancer Cell; 2024 Sep; 42(9):1582-1597.e10. PubMed ID: 39214097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model.
    Zhu J; Yu M; Chen L; Kong P; Li L; Ma G; Ge H; Cui Y; Li Z; Pan H; Xie H; Zhou W; Wang S
    Diagn Interv Imaging; 2018 Mar; 99(3):135-142. PubMed ID: 29398572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
    Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
    Anagnostou V; Smith KN; Forde PM; Niknafs N; Bhattacharya R; White J; Zhang T; Adleff V; Phallen J; Wali N; Hruban C; Guthrie VB; Rodgers K; Naidoo J; Kang H; Sharfman W; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Zahnow CA; Baylin SB; Scharpf RB; Brahmer JR; Karchin R; Pardoll DM; Velculescu VE
    Cancer Discov; 2017 Mar; 7(3):264-276. PubMed ID: 28031159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
    Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
    Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
    Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
    Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
    Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?
    Sabanathan D; Park JJ; Marquez M; Francisco L; Byrne N; Gurney H
    Oncologist; 2017 Dec; 22(12):1470-1477. PubMed ID: 29146617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.
    McCaw TR; Li M; Starenki D; Cooper SJ; Liu M; Meza-Perez S; Arend RC; Buchsbaum DJ; Forero A; Randall TD
    Cancer Immunol Immunother; 2019 Feb; 68(2):175-188. PubMed ID: 30334128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential Response of MDA-MB-231 and MCF-7 Breast Cancer Cells to In Vitro Inhibition with CTLA-4 and PD-1 through Cancer-Immune Cells Modified Interactions.
    Grubczak K; Kretowska-Grunwald A; Groth D; Poplawska I; Eljaszewicz A; Bolkun L; Starosz A; Holl JM; Mysliwiec M; Kruszewska J; Wojtukiewicz MZ; Moniuszko M
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Live or Let Die: T Cell Survival in Cancer Immunotherapy.
    Ruotsalainen J; Tüting T
    Immunity; 2019 Feb; 50(2):280-282. PubMed ID: 30784574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
    Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
    Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
    Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
    Chen X; Song X; Li K; Zhang T
    Front Immunol; 2019; 10():292. PubMed ID: 30863404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy.
    Klepsch V; Hermann-Kleiter N; Baier G
    Immunol Lett; 2016 Oct; 178():31-6. PubMed ID: 26992368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indicators of responsiveness to immune checkpoint inhibitors.
    Shields BD; Mahmoud F; Taylor EM; Byrum SD; Sengupta D; Koss B; Baldini G; Ransom S; Cline K; Mackintosh SG; Edmondson RD; Shalin S; Tackett AJ
    Sci Rep; 2017 Apr; 7(1):807. PubMed ID: 28400597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.